Anzeige
Mehr »
Donnerstag, 17.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41556 | ISIN: US87978U2078 | Ticker-Symbol: 3OS0
Lang & Schwarz
17.07.25 | 07:00
6,010 Euro
-100,00 % -6,010
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
TEMPEST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TEMPEST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,9206,10007:00

Aktuelle News zur TEMPEST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
30.06.Tempest Therapeutics: Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China222Builds on clearances already received by FDA and EMAChina has the largest population of patients with hepatocellular carcinoma in the world BRISBANE, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Tempest...
► Artikel lesen
TEMPEST THERAPEUTICS Aktie jetzt für 0€ handeln
12.06.Tempest Therapeutics Announces $4.6 Mln Registered Direct Offering With Institutional Investor13
11.06.Tempest Therapeutics: Tempest Announces $4.6 Million Registered Direct Offering of Common Stock3
11.06.Tempest Therapeutics announces $4.6 million registered direct offering1
06.06.Tempest Therapeutics, Inc. - 8-K, Current Report16
06.06.TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy15
05.06.Tempest Therapeutics-Aktie steigt nach EMA-Orphan-Drug-Designation8
05.06.Tempest Therapeutics stock rises on EMA Orphan Drug Designation3
05.06.Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat4
13.05.Tempest Therapeutics GAAP EPS of -$3.16 misses by $0.0122
13.05.Tempest Therapeutics Inc. Loss At -$10.86 Mln In Q18
13.05.Tempest Therapeutics, Inc. - 10-Q, Quarterly Report5
13.05.Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update358Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment...
► Artikel lesen
13.05.Tempest Therapeutics, Inc. - 8-K, Current Report2
28.04.Tempest Therapeutics: Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting19
28.04.Tempest Therapeutics, Inc. - 8-K, Current Report7
21.04.Tempest Therapeutics-Aktie steigt nach FDA-Orphan-Drug-Designation41
21.04.Tempest Therapeutics stock rises on FDA Orphan Drug Designation4
21.04.Tempest Therapeutics: FDA Grants Orphan Drug Designation To TPST-14954
21.04.Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP468BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics...
► Artikel lesen
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1